北芯生命开启申购 专注于心血管疾病诊疗领域

Core Viewpoint - Beixin Life (688712.SH) has launched its subscription with an issue price of 17.52 yuan per share, aiming to innovate in cardiovascular disease diagnosis and treatment through advanced medical devices [1] Company Overview - Beixin Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] - The company plans to launch a total of 11 products by September 30, 2025, with 6 products currently under development, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [1] Key Products - The core product, the IVUS system, is China's first domestically developed 60MHz high-definition and high-speed IVUS product, designed to efficiently guide precise PCI strategy formulation [1] - The FFR measurement system is the first domestically approved product in China within the gold standard FFR field, both products are undergoing special review procedures for innovative medical devices [1] Market Position - After launching, the core products quickly captured the second-largest market share domestically and the largest share among domestic brands, contributing to the increase in the localization rate of high-end active interventional medical devices [1] Financial Performance - Revenue for the years 2022, 2023, 2024, and the first half of 2025 is approximately 92.45 million yuan, 184 million yuan, 317 million yuan, and 259 million yuan respectively, with net profits of -30 million yuan, -15.55 million yuan, -5.37 million yuan, and 4.55 million yuan [2] - As of June 30, 2025, total assets are approximately 838.54 million yuan, with equity attributable to the parent company at 755.23 million yuan and a debt-to-asset ratio of 15.20% [3]